Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 500674 | NSE: SANOFI

Sanofi India Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 10:54 am

Market Cap 12,624 Cr.
Current Price 5,482
High / Low 7,600/4,146
Stock P/E34.8
Book Value 374
Dividend Yield3.05 %
ROCE49.2 %
ROE38.6 %
Face Value 10.0
PEG Ratio-12.25

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Sanofi India Ltd

Competitors of Sanofi India Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,255.37 Cr1,081.8442.42185.800.37%16.00%16.32%6.27

All Competitor Stocks of Sanofi India Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 688707699692672736515491469511464524515
Expenses 561512538510505507393377370374348404397
Operating Profit 127194161182167230122114100137116120118
OPM % 18%28%23%26%25%31%24%23%21%27%25%23%23%
Other Income 16142161134445782774121214
Interest 0000001000000
Depreciation 11111110101099999910
Profit before tax 132326166182190264169186167169127113122
Tax % 32%27%27%28%31%28%27%18%18%19%19%27%25%
Net Profit 902381201311311901231521381371038291
EPS in Rs 39.30103.6552.3556.9156.9182.7853.4366.1759.8759.3944.9635.7439.70

Last Updated: February 28, 2025, 5:20 pm

Below is a detailed analysis of the quarterly data for Sanofi India Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹515.00 Cr.. The value appears to be declining and may need further review. It has decreased from 524.00 Cr. (Sep 2024) to ₹515.00 Cr., marking a decrease of 9.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹397.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 404.00 Cr. (Sep 2024) to ₹397.00 Cr., marking a decrease of 7.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹118.00 Cr.. The value appears to be declining and may need further review. It has decreased from 120.00 Cr. (Sep 2024) to ₹118.00 Cr., marking a decrease of 2.00 Cr..
  • For OPM %, as of Dec 2024, the value is 23.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 23.00%.
  • For Other Income, as of Dec 2024, the value is ₹14.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2024) to ₹14.00 Cr., marking an increase of ₹12.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹10.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.00 Cr. (Sep 2024) to ₹10.00 Cr., marking an increase of ₹1.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹122.00 Cr.. The value appears strong and on an upward trend. It has increased from 113.00 Cr. (Sep 2024) to ₹122.00 Cr., marking an increase of ₹9.00 Cr..
  • For Tax %, as of Dec 2024, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Sep 2024) to 25.00%, marking a decrease of 2.00%.
  • For Net Profit, as of Dec 2024, the value is ₹91.00 Cr.. The value appears strong and on an upward trend. It has increased from 82.00 Cr. (Sep 2024) to ₹91.00 Cr., marking an increase of ₹9.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 39.70. The value appears strong and on an upward trend. It has increased from ₹35.74 (Sep 2024) to 39.70, marking an increase of ₹3.96.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 6:57 pm

MetricDec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales 1,8091,9772,1932,3672,4602,7713,0712,9022,9572,7702,8512,013
Expenses 1,4111,6391,8171,8321,9212,1462,4032,1862,1942,0662,0471,522
Operating Profit 398339376535538625667716762704804491
OPM % 22%17%17%23%22%23%22%25%26%25%28%24%
Other Income 8313121866798833455642048379
Interest 000211022222
Depreciation 92971131191021031008267424037
Profit before tax 3883734814805156106006771,258864846531
Tax % 32%29%33%37%37%38%31%29%25%28%29%22%
Net Profit 265264322304326381414478944621603414
EPS in Rs 115.30114.61139.78132.26141.74165.48180.09207.65410.61269.83262.26179.78
Dividend Payout % 39%39%46%51%50%51%194%176%119%211%64%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year
YoY Net Profit Growth (%)
Change in YoY Net Profit Growth (%)

No data available for trend analysis.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: February 12, 2025, 2:55 pm

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Jun 2024
Equity Capital 23232323232323232323232323
Reserves 1,1811,3241,4631,6041,8602,0032,1962,4192,0962,2031,253992662
Borrowings -0-0-0-0-0-0-0-02325241922
Other Liabilities 427532742778658751765802777811772681654
Total Liabilities 1,6311,8782,2282,4052,5412,7782,9843,2442,9183,0612,0721,7151,360
Fixed Assets 699699648877817769733499464334306315302
CWIP 4313621022343021171013241629
Investments 0000000-0-0-0-02-0
Other Assets 8881,0431,3691,5051,6901,9782,2302,7282,4442,7141,7431,3821,029
Total Assets 1,6311,8782,2282,4052,5412,7782,9843,2442,9183,0612,0721,7151,360

Below is a detailed analysis of the balance sheet data for Sanofi India Ltd based on the most recent figures (Jun 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Jun 2024, the value is ₹23.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2023) which recorded ₹23.00 Cr..
  • For Reserves, as of Jun 2024, the value is ₹662.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹992.00 Cr. (Dec 2023) to ₹662.00 Cr., marking a decrease of 330.00 Cr..
  • For Borrowings, as of Jun 2024, the value is ₹22.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹19.00 Cr. (Dec 2023) to ₹22.00 Cr., marking an increase of 3.00 Cr..
  • For Other Liabilities, as of Jun 2024, the value is ₹654.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹681.00 Cr. (Dec 2023) to ₹654.00 Cr., marking a decrease of 27.00 Cr..
  • For Total Liabilities, as of Jun 2024, the value is ₹1,360.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹1,715.00 Cr. (Dec 2023) to ₹1,360.00 Cr., marking a decrease of 355.00 Cr..
  • For Fixed Assets, as of Jun 2024, the value is ₹302.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹315.00 Cr. (Dec 2023) to ₹302.00 Cr., marking a decrease of 13.00 Cr..
  • For CWIP, as of Jun 2024, the value is ₹29.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹16.00 Cr. (Dec 2023) to ₹29.00 Cr., marking an increase of 13.00 Cr..
  • For Investments, as of Jun 2024, the value is ₹0.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹2.00 Cr. (Dec 2023) to ₹0.00 Cr., marking a decrease of 2.00 Cr..
  • For Other Assets, as of Jun 2024, the value is ₹1,029.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹1,382.00 Cr. (Dec 2023) to ₹1,029.00 Cr., marking a decrease of 353.00 Cr..
  • For Total Assets, as of Jun 2024, the value is ₹1,360.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹1,715.00 Cr. (Dec 2023) to ₹1,360.00 Cr., marking a decrease of 355.00 Cr..

Notably, the Reserves (₹662.00 Cr.) exceed the Borrowings (22.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

MonthDec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Free Cash Flow398.00339.00376.00535.00538.00625.00667.00693.00737.00680.00785.00491.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023
Debtor Days232421242229212719181717
Inventory Days135151179173169151154127107110125202
Days Payable758312281791191101009310510989
Cash Conversion Cycle839278115112616554332233130
Working Capital Days34326979171835-7-19-1825
ROCE %23%29%22%26%27%26%29%28%32%35%41%71%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%
FIIs9.22%8.99%8.71%8.26%6.99%6.71%6.72%6.80%6.31%6.11%5.81%5.78%
DIIs19.05%18.65%18.59%18.28%19.22%19.46%19.65%21.68%22.51%22.88%22.60%22.62%
Public11.33%11.96%12.30%13.08%13.41%13.43%13.22%11.10%10.78%10.61%11.21%11.20%
No. of Shareholders50,91659,27664,54273,73474,59376,69471,51368,59862,87061,84967,66266,211

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Aditya Birla Sun Life Frontline Equity Fund268,5080.84216.62152,3712025-03-1176.22%
Nippon India Pharma Fund236,0082.94190.4152,3712025-03-1154.89%
Nippon India Growth Fund226,7660.78182.94152,3712025-03-1148.82%
Nippon India Small Cap Fund196,3420.36158.4152,3712025-03-1128.86%
SBI Contra Fund161,0000.68129.5152,3712025-03-115.66%
Nippon India Multi Cap Fund152,3710.5122.93152,3712025-03-110%
SBI Long Term Equity Fund147,9880.69119.04152,3712025-03-11-2.88%
Aditya Birla Sun Life Small Cap Fund144,4332.22116.52152,3712025-03-11-5.21%
SBI Magnum Midcap Fund100,8370.5681.11152,3712025-03-11-33.82%
Aditya Birla Sun Life Multi-Cap Fund87,3421.4370.46152,3712025-03-11-42.68%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthDec 23
FaceValue 10.00
Basic EPS (Rs.) 261.78
Diluted EPS (Rs.) 261.78
Cash EPS (Rs.) 279.35
Book Value[Excl.RevalReserv]/Share (Rs.) 441.39
Book Value[Incl.RevalReserv]/Share (Rs.) 441.39
Revenue From Operations / Share (Rs.) 1239.61
PBDIT / Share (Rs.) 377.83
PBIT / Share (Rs.) 360.61
PBT / Share (Rs.) 367.61
Net Profit / Share (Rs.) 262.13
NP After MI And SOA / Share (Rs.) 262.13
PBDIT Margin (%) 30.47
PBIT Margin (%) 29.09
PBT Margin (%) 29.65
Net Profit Margin (%) 21.14
NP After MI And SOA Margin (%) 21.14
Return on Networth / Equity (%) 59.38
Return on Capital Employeed (%) 77.98
Return On Assets (%) 35.15
Current Ratio (X) 1.92
Quick Ratio (X) 0.89
Dividend Payout Ratio (NP) (%) 139.85
Dividend Payout Ratio (CP) (%) 131.23
Earning Retention Ratio (%) -39.85
Cash Earning Retention Ratio (%) -31.23
Interest Coverage Ratio (X) 511.18
Interest Coverage Ratio (Post Tax) (X) 345.18
Enterprise Value (Cr.) 18147.83
EV / Net Operating Revenue (X) 6.37
EV / EBITDA (X) 20.88
MarketCap / Net Operating Revenue (X) 6.51
Retention Ratios (%) -39.85
Price / BV (X) 18.28
Price / Net Operating Revenue (X) 6.51
EarningsYield 0.03

After reviewing the key financial ratios for Sanofi India Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Dec 23, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
  • For Basic EPS (Rs.), as of Dec 23, the value is 261.78. This value is within the healthy range. No previous period data is available for comparison.
  • For Diluted EPS (Rs.), as of Dec 23, the value is 261.78. This value is within the healthy range. No previous period data is available for comparison.
  • For Cash EPS (Rs.), as of Dec 23, the value is 279.35. This value is within the healthy range. No previous period data is available for comparison.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Dec 23, the value is 441.39. No previous period data is available for comparison.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Dec 23, the value is 441.39. No previous period data is available for comparison.
  • For Revenue From Operations / Share (Rs.), as of Dec 23, the value is 1,239.61. No previous period data is available for comparison.
  • For PBDIT / Share (Rs.), as of Dec 23, the value is 377.83. This value is within the healthy range. No previous period data is available for comparison.
  • For PBIT / Share (Rs.), as of Dec 23, the value is 360.61. This value is within the healthy range. No previous period data is available for comparison.
  • For PBT / Share (Rs.), as of Dec 23, the value is 367.61. This value is within the healthy range. No previous period data is available for comparison.
  • For Net Profit / Share (Rs.), as of Dec 23, the value is 262.13. This value is within the healthy range. No previous period data is available for comparison.
  • For NP After MI And SOA / Share (Rs.), as of Dec 23, the value is 262.13. This value is within the healthy range. No previous period data is available for comparison.
  • For PBDIT Margin (%), as of Dec 23, the value is 30.47. This value is within the healthy range. No previous period data is available for comparison.
  • For PBIT Margin (%), as of Dec 23, the value is 29.09. This value exceeds the healthy maximum of 20. No previous period data is available for comparison.
  • For PBT Margin (%), as of Dec 23, the value is 29.65. This value is within the healthy range. No previous period data is available for comparison.
  • For Net Profit Margin (%), as of Dec 23, the value is 21.14. This value exceeds the healthy maximum of 10. No previous period data is available for comparison.
  • For NP After MI And SOA Margin (%), as of Dec 23, the value is 21.14. This value exceeds the healthy maximum of 20. No previous period data is available for comparison.
  • For Return on Networth / Equity (%), as of Dec 23, the value is 59.38. This value is within the healthy range. No previous period data is available for comparison.
  • For Return on Capital Employeed (%), as of Dec 23, the value is 77.98. This value is within the healthy range. No previous period data is available for comparison.
  • For Return On Assets (%), as of Dec 23, the value is 35.15. This value is within the healthy range. No previous period data is available for comparison.
  • For Current Ratio (X), as of Dec 23, the value is 1.92. This value is within the healthy range. No previous period data is available for comparison.
  • For Quick Ratio (X), as of Dec 23, the value is 0.89. This value is below the healthy minimum of 1. No previous period data is available for comparison.
  • For Dividend Payout Ratio (NP) (%), as of Dec 23, the value is 139.85. This value exceeds the healthy maximum of 50. No previous period data is available for comparison.
  • For Dividend Payout Ratio (CP) (%), as of Dec 23, the value is 131.23. This value exceeds the healthy maximum of 50. No previous period data is available for comparison.
  • For Earning Retention Ratio (%), as of Dec 23, the value is -39.85. This value is below the healthy minimum of 40. No previous period data is available for comparison.
  • For Cash Earning Retention Ratio (%), as of Dec 23, the value is -31.23. This value is below the healthy minimum of 40. No previous period data is available for comparison.
  • For Interest Coverage Ratio (X), as of Dec 23, the value is 511.18. This value is within the healthy range. No previous period data is available for comparison.
  • For Interest Coverage Ratio (Post Tax) (X), as of Dec 23, the value is 345.18. This value is within the healthy range. No previous period data is available for comparison.
  • For Enterprise Value (Cr.), as of Dec 23, the value is 18,147.83. No previous period data is available for comparison.
  • For EV / Net Operating Revenue (X), as of Dec 23, the value is 6.37. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
  • For EV / EBITDA (X), as of Dec 23, the value is 20.88. This value exceeds the healthy maximum of 15. No previous period data is available for comparison.
  • For MarketCap / Net Operating Revenue (X), as of Dec 23, the value is 6.51. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
  • For Retention Ratios (%), as of Dec 23, the value is -39.85. This value is below the healthy minimum of 30. No previous period data is available for comparison.
  • For Price / BV (X), as of Dec 23, the value is 18.28. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
  • For Price / Net Operating Revenue (X), as of Dec 23, the value is 6.51. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
  • For EarningsYield, as of Dec 23, the value is 0.03. This value is below the healthy minimum of 5. No previous period data is available for comparison.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Sanofi India Ltd as of March 12, 2025 is: ₹4,141.68

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Sanofi India Ltd is Overvalued by 24.45% compared to the current share price 5,482.00

Intrinsic Value of Sanofi India Ltd as of March 12, 2025 is: 4,024.00

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Sanofi India Ltd is Overvalued by 26.60% compared to the current share price 5,482.00

Last 5 Year EPS CAGR: -2.84%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 32.42%, which is a positive sign.
  2. The stock has a low average Working Capital Days of 17.58, which is a positive sign.
  3. The company has higher reserves (1,635.08 cr) compared to borrowings (8.69 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (1.92 cr) and profit (530.50 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 73.17, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sanofi India Ltd:
    1. Net Profit Margin: 21.14%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 77.98% (Industry Average ROCE: 16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 59.38% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 345.18
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.89
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 34.8 (Industry average Stock P/E: 42.42)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Sanofi India Ltd. is a Public Limited Listed company incorporated on 02/05/1956 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1956PLC009794 and registration number is 009794. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 2013.20 Cr. and Equity Capital is Rs. 23.00 Cr. for the Year ended 31/12/2024.
INDUSTRYADDRESSCONTACT
PharmaceuticalsSanofi House, Mumbai Maharashtra 400072igrc.sil@sanofi.com
http://www.sanofiindialtd.com
Management
NamePosition Held
Mr. Aditya NarayanChairman & Ind.Director
Mr. Rodolfo HroszManaging Director
Mr. Rachid AyariWholeTime Director & CFO
Ms. Renee AmonkarWhole Time Director
Mr. Vaibhav KarandikarNon Executive Director
Mrs. Usha ThoratIndependent Director
Mr. Rahul BhatnagarIndependent Director

FAQ

What is the latest intrinsic value of Sanofi India Ltd?

The latest intrinsic value of Sanofi India Ltd as on 08 March 2025 is ₹4141.68, which is 24.45% lower than the current market price of 5,482.00, indicating the stock is overvalued by 24.45%. The intrinsic value of Sanofi India Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹12,624 Cr. and recorded a high/low of ₹7,600/4,146 during the current fiscal year 2024-2025. As of Jun 2024, the company has reserves of ₹662 Cr and total liabilities of ₹1,360 Cr.

What is the Market Cap of Sanofi India Ltd?

The Market Cap of Sanofi India Ltd is 12,624 Cr..

What is the current Stock Price of Sanofi India Ltd as on 08 March 2025?

The current stock price of Sanofi India Ltd as on 08 March 2025 is ₹5,482.

What is the High / Low of Sanofi India Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Sanofi India Ltd stocks is ₹7,600/4,146.

What is the Stock P/E of Sanofi India Ltd?

The Stock P/E of Sanofi India Ltd is 34.8.

What is the Book Value of Sanofi India Ltd?

The Book Value of Sanofi India Ltd is 374.

What is the Dividend Yield of Sanofi India Ltd?

The Dividend Yield of Sanofi India Ltd is 3.05 %.

What is the ROCE of Sanofi India Ltd?

The ROCE of Sanofi India Ltd is 49.2 %.

What is the ROE of Sanofi India Ltd?

The ROE of Sanofi India Ltd is 38.6 %.

What is the Face Value of Sanofi India Ltd?

The Face Value of Sanofi India Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Sanofi India Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE